Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Ibuprofen sodium

Ibuprofen sodium: 1 brand, 1 generic; first approved Jun 12, 2012; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 1 ANDA application approved.

Brands (NDA)
1
Generics (ANDA)
1
Listed patents
0
Presentations
2

Brand (NDA) products

Originator applications
  • ADVILRLDRS
    NDA 2018032012
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 200MG BASETABLETORALOTC—

Generic (ANDA) products (1)

Abbreviated applications
  • IBUPROFEN SODIUM
    ANDA 2065812015
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 200MG BASETABLETORALDiscontinued—

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
14 yr 6 mo ago
Most recent approval
11 yr 4 mo ago

Approvals span 2012–2015 across 2 FDA applications.

Brand (NDA) 150%
Generic (ANDA) 150%

Ibuprofen sodium: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Go beyond the database.

Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.